Angiogenesis is the growth of new blood vessels from vessels that already exist. It is one of three ways the body builds and expands its vascular network. In vasculogenesis, vessels form from scratch out of endothelial precursor cells; in arteriogenesis, small existing connections between arteries widen into larger collateral arteries.[1][2] Vasculogenesis builds the first vessels of the embryo. Angiogenesis continues in adults, for example when wounds heal and when the lining of the womb regrows in each menstrual cycle, and abnormal angiogenesis is part of cancer and several eye diseases.[1] Arteriogenesis is how collateral arteries grow around a narrowed or blocked artery.[2] The table sets the three processes side by side; the sections below explain each, then what is known about using them as treatment.
| Process | What happens | Main trigger |
|---|---|---|
| Angiogenesis | New capillaries sprout from, or split off, existing vessels | Low oxygen (hypoxia), which raises growth factors such as VEGF[1] |
| Vasculogenesis | Endothelial precursor cells (angioblasts) gather and form new vessel tubes; in the embryo this builds the first vessels[1] | Embryonic development; whether it contributes much in adults is debated[1] |
| Arteriogenesis | Pre-existing small artery-to-artery connections enlarge into functional collateral arteries[2] | Increased blood flow and shear stress on the vessel wall, for example around a blocked artery[2] |
Brief Overview of Angiogenesis
Blood vessels are lined by endothelial cells, and angiogenesis is driven by these cells. Tissues cannot grow far without a blood supply: it has been estimated that tissue growth beyond about one cubic millimetre already needs new vessels.[1] When a tissue becomes short of oxygen, it releases pro-angiogenic growth factors such as vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF), which bind receptors on endothelial cells. Whether vessels actually grow depends on the balance between these stimulators and the body’s natural inhibitors, a balance often called the angiogenic switch.[1][3] Normally the two sides are balanced so that vessels form only when and where they are needed, such as during growth and healing.[3]
Healthy tissues adjust their capillaries to demand. In a study of five people who trained on an exercise bicycle for eight weeks, capillary density in the thigh muscle rose by 20%.[4] Fat tissue is one of the most densely vascularised tissues in the body, with every fat cell touching at least one capillary, and in mice that become obese, the volume of blood vessels in fat tissue increases.[1] The stromal cells that surround these vessels are described on our page on the stromal vascular fraction of fat tissue.
Angiogenesis Subtypes
There are two main forms of angiogenesis. In sprouting angiogenesis, a specialised endothelial cell called a tip cell breaks out of the vessel wall and moves toward the source of VEGF, guided by thin projections called filopodia. Stalk cells behind it divide and form a hollow tube, and the sprout joins another sprout or vessel so that blood can flow. Which cell leads may depend partly on small differences in VEGF receptor levels, and tip and stalk cells can swap places as the sprout grows, a switch that needs Notch signalling.[1] Sprouting adds vessels to tissue that has too few.
In intussusceptive angiogenesis, an existing vessel splits in two. Endothelial cells on opposite sides of the vessel reach across the channel and form a column of tissue, a pillar, which widens until there are two vessels. The process was first seen in the remodelling of lung capillaries after birth; because it does not need cells to divide at first, it can happen within hours or even minutes.[1] Pillars are also used to prune redundant vessels and to change the angle at which vessels branch.[5] Splitting is hard to see with an ordinary light microscope, which is one reason it is less studied than sprouting.[5]
Vasculogenesis and Endothelial Progenitor Cells
In the early embryo, clusters called blood islands form in the mesoderm. Their cells give rise to angioblasts, precursor cells that carry the VEGF receptor VEGFR2, and these join into simple endothelial tubes. This is vasculogenesis, and it builds the first blood vessels; most later growth happens by angiogenesis.[1]
Whether vasculogenesis also happens in adults has been argued for almost 30 years. In 1997, researchers isolated cells from human blood that turned into endothelial-like cells in culture and settled in growing vessels in animal models of poor blood flow; they called them putative endothelial progenitor cells (EPCs).[6] Later work split this group apart. Colonies counted in a widely used commercial kit turned out to come from the blood-forming system: they behaved like myeloid cells, became macrophages and did not form perfused vessels when implanted in mice. A different, rare cell type, the endothelial colony-forming cell (ECFC), did form working vessels.[7] An expert consensus statement in 2017 asked researchers to stop using “EPC” loosely and to separate true endothelial progenitors from blood cells that help vessel repair by releasing signals.[8]
ECFCs are scarce in human blood, roughly 0.05 to 0.2 cells per millilitre. In mice, lineage tracing has found that cells with ECFC properties come from the vessel wall rather than the bone marrow, and how much circulating cells contribute to new vessels in adults is still unsettled.[1] Studies of tumours reached a similar conclusion: bone marrow-derived endothelial progenitors are not needed for tumour angiogenesis, while blood cells that enter tumours may support vessel growth by releasing signals.[9]
Role of Angiogenesis in Stem Cell Therapies
Cell therapies for poor circulation were first designed on the idea that injected cells would become new vessel walls. That idea was increasingly challenged, and attention moved to the signals that blood-derived cells and stem cells release, a form of paracrine signalling.[2] Human and mouse bone marrow mesenchymal stromal cells (MSCs) grown in the laboratory release VEGF, basic FGF, placental growth factor and other factors, and the fluid they were grown in made endothelial cells divide and migrate; in mice with a tied-off leg artery, injected MSCs improved blood flow without being found inside the new collateral vessels.[10][11] Stromal cells from human fat released VEGF, hepatocyte growth factor (HGF) and transforming growth factor beta in culture, released five times more VEGF when oxygen was low, and improved blood flow in the ischaemic legs of mice.[12] These are laboratory and animal findings. They explain why such cells are tested in limb and heart disease; they do not show that the cells work in people.
Therapeutic angiogenesis has been tested in people in three forms: growth factor proteins, gene therapy that makes the body produce a growth factor, and cell-based therapies. One of the first human uses was a small, early study reported in 1998, in which FGF-1 was injected near the new bypass graft in 20 people having heart bypass surgery, with new small vessels seen on imaging 12 weeks later.[13] The large placebo-controlled trials that followed were mostly negative. Large trials include:
| Treatment and condition | Design and size | Main result |
|---|---|---|
| Rexlemestrocel-L, donor mesenchymal precursor cells injected into the heart wall; heart failure with reduced ejection fraction (DREAM-HF)[14] | Randomised, double-blind, sham-controlled; 565 patients | No benefit on the primary endpoint (recurrent heart failure or arrhythmia events) or the secondary endpoints; fewer heart attacks and strokes in an exploratory analysis |
| NV1FGF, an FGF gene injected into leg muscle; critical limb ischaemia (TAMARIS)[15] | Phase 3, randomised, placebo-controlled; 525 patients | No benefit: amputation or death at one year in 36% with the gene and 33% with placebo |
| Bone marrow mononuclear cells infused into the coronary artery after a heart attack (BAMI)[16] | Randomised, open-label; 375 patients | Deaths at two years 3.3% with cells and 3.8% without; too few patients and events to draw any conclusion |
| Cardiopoietic cells, the patient’s own MSCs conditioned in the laboratory, injected into the heart; ischaemic heart failure (CHART-1)[17] | Randomised, double-blind, sham-controlled; 315 patients | No benefit on the primary combined endpoint at 39 weeks |
| PLX-PAD, placenta-derived stromal cells injected into leg muscle; critical limb ischaemia (PACE)[18] | Phase 3, randomised, placebo-controlled; 213 patients | No benefit: major amputation or death in 28.6% with cells and 33% with placebo; a better result in a post hoc analysis of 121 patients without diabetes or with well-controlled diabetes needs confirmation |
| Recombinant VEGF protein infused into the coronary artery and veins; angina (VIVA)[19] | Randomised, double-blind, placebo-controlled; 178 patients | No difference from placebo at 60 days; less angina with the high dose at 120 days |
| The patient’s own bone marrow mononuclear cells infused into the leg artery three times; limb ischaemia with no surgical option (JUVENTAS)[20] | Randomised, double-blind, placebo-controlled; 160 patients | No benefit: major amputation at six months in 19% with cells and 13% with placebo |
Pooled analyses point the same way. Across 10 placebo-controlled trials of bone marrow cells in critical limb ischaemia, with 499 patients, amputation, survival and amputation-free survival did not differ between cells and placebo; ankle pressure, skin oxygen and pain scores were somewhat better with cells.[21] In JUVENTAS, quality of life, rest pain and blood-flow measures improved in both the cell and the placebo group, which is why placebo controls matter in these trials.[20] A Cochrane review of 38 randomised trials with 1,907 people with chronic ischaemic heart disease or heart failure found that bone marrow cells reduced long-term deaths, but rated the evidence as low quality: events were few, and 23 of the 38 trials were at high or unclear risk of bias in how patients were allocated.[22] One early trial of cardiac stem cells in heart failure, SCIPIO, was retracted by The Lancet in 2019.[23]
As of November 2026, the US Food and Drug Administration list of approved cellular and gene therapy products contains no product for limb ischaemia or for heart disease.[24] Japan has a conditional, time-limited approval pathway for regenerative products. Beperminogene perplasmid (Collategene), a plasmid carrying the HGF gene that was tested in critical limb ischaemia in a placebo-controlled trial of 44 patients,[25] was approved this way in March 2019, and its marketing authorisation has since expired. HeartSheet, sheets made from the patient’s own skeletal muscle cells, was conditionally approved in 2015 and refused full approval in July 2024.[26] RiHEART, heart muscle cell sheets made from donor induced pluripotent stem cells, received a conditional, time-limited approval for ischaemic cardiomyopathy on 6 March 2026; its benefit has to be confirmed after marketing.[27] The heart and blood vessels are described on our page on the cardiovascular system; donor-derived cells such as those in DREAM-HF and PACE are explained on our page on allogeneic (donor) stem cells.
Angiogenesis in tumours
In 1971, Judah Folkman proposed that tumours cannot grow without new blood vessels and that blocking angiogenesis could treat cancer.[28][29] Solid tumours need a blood supply to grow beyond a few millimetres; they release signals that stimulate angiogenesis and recruit nearby normal cells to do the same, and the new vessels also give cancer cells a route to spread.[3] In one study of colon cancer grown in mice, about 15% of perfused vessels were “mosaic” vessels, with patches where cancer cells rather than endothelial cells lined the channel, and similar numbers were seen in biopsies from people with colon cancer.[30] Not every tumour depends on new vessels: some grow along existing vessels instead, a process called vessel co-option.[1]
The first anti-angiogenic cancer drug, bevacizumab, was approved in the United States in 2004 for metastatic colon cancer.[29] It is an antibody that blocks VEGF, and its label covers metastatic colorectal cancer, non-small cell lung cancer, recurrent glioblastoma, kidney cancer and other cancers, often in combination with other cancer drugs.[31] Ramucirumab blocks the VEGF receptor VEGFR2 and is used in stomach and lung cancer, among others,[32] and ziv-aflibercept, a VEGF trap, is used with chemotherapy in metastatic colorectal cancer.[33] Their labels warn of bleeding, perforation of the bowel and poor wound healing, which is why they are stopped before and after surgery.[31][32][33] Other side effects of this drug class include high blood pressure, protein in the urine and clots in the arteries.[3]
Resistance is a limit of these drugs. In both mouse models and patients, the benefit of drugs that block VEGF is often temporary, and tumours resume growth by switching to other angiogenic signals or by not depending on VEGF in the first place.[34]
Blocking angiogenesis is also routine in eye medicine. Abnormal vessel growth causes wet age-related macular degeneration,[3] and VEGF inhibitors injected into the eye, such as ranibizumab and aflibercept, are approved for wet macular degeneration, diabetic macular oedema, diabetic retinopathy and macular oedema after retinal vein occlusion.[35][36]
What is neuroangiogenesis?
Neuroangiogenesis is the coordinated growth of new nerve fibres and new blood vessels. Nerves and vessels often run side by side, and the guidance molecules that steer growing axons to their targets, by attraction and repulsion, also steer growing vessels; some growth factors act on both.[37] In mice, after a stroke, newly made neurons migrate from the brain’s stem cell zone into the damaged cortex and gather around remodelling blood vessels, and two signals produced by the vessels, SDF1 and angiopoietin 1, linked the two processes and supported recovery.[38] In endometriosis, a common cause of pelvic pain, the misplaced tissue recruits its own nerve fibres and blood vessels, and these new nerves are thought to increase pain.[39] More on how the brain’s vessels control what reaches nerve tissue is on our page on the blood-brain barrier.
Published Clinical Citations
[1] ^ Dudley AC, Griffioen AW. Pathological angiogenesis: mechanisms and therapeutic strategies. Angiogenesis. 2023;26(3):313-347. https://doi.org/10.1007/s10456-023-09876-7
[2] ^ Heil M, Eitenmüller I, Schmitz-Rixen T, et al. Arteriogenesis versus angiogenesis: similarities and differences. J Cell Mol Med. 2006;10(1):45-55. https://doi.org/10.1111/j.1582-4934.2006.tb00290.x
[3] ^ National Cancer Institute. Angiogenesis inhibitors (fact sheet, reviewed 2 April 2018). https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/angiogenesis-inhibitors-fact-sheet
[4] ^ Andersen P, Henriksson J. Capillary supply of the quadriceps femoris muscle of man: adaptive response to exercise. J Physiol. 1977;270(3):677-90. https://doi.org/10.1113/jphysiol.1977.sp011975
[5] ^ Mentzer SJ, Konerding MA. Intussusceptive angiogenesis: expansion and remodeling of microvascular networks. Angiogenesis. 2014;17(3):499-509. https://doi.org/10.1007/s10456-014-9428-3
[6] ^ Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275(5302):964-7. https://doi.org/10.1126/science.275.5302.964
[7] ^ Yoder MC, Mead LE, Prater D, et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood. 2007;109(5):1801-9. https://doi.org/10.1182/blood-2006-08-043471
[8] ^ Medina RJ, Barber CL, Sabatier F, et al. Endothelial Progenitors: A Consensus Statement on Nomenclature. Stem Cells Transl Med. 2017;6(5):1316-1320. https://doi.org/10.1002/sctm.16-0360
[9] ^ Fang S, Salven P. Stem cells in tumor angiogenesis. J Mol Cell Cardiol. 2011;50(2):290-5. https://doi.org/10.1016/j.yjmcc.2010.10.024
[10] ^ Kinnaird T, Stabile E, Burnett MS, et al. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res. 2004;94(5):678-85. https://doi.org/10.1161/01.RES.0000118601.37875.AC
[11] ^ Kinnaird T, Stabile E, Burnett MS, et al. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation. 2004;109(12):1543-9. https://doi.org/10.1161/01.CIR.0000124062.31102.57
[12] ^ Rehman J, Traktuev D, Li J, et al. Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation. 2004;109(10):1292-8. https://doi.org/10.1161/01.CIR.0000121425.42966.F1
[13] ^ Schumacher B, Pecher P, von Specht BU, et al. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation. 1998;97(7):645-50. https://doi.org/10.1161/01.cir.97.7.645
[14] ^ Perin EC, Borow KM, Henry TD, et al. Randomized Trial of Targeted Transendocardial Mesenchymal Precursor Cell Therapy in Patients With Heart Failure. J Am Coll Cardiol. 2023;81(9):849-863. https://doi.org/10.1016/j.jacc.2022.11.061
[15] ^ Belch J, Hiatt WR, Baumgartner I, et al. Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet. 2011;377(9781):1929-37. https://doi.org/10.1016/S0140-6736(11)60394-2
[16] ^ Mathur A, Fernández-Avilés F, Bartunek J, et al. The effect of intracoronary infusion of bone marrow-derived mononuclear cells on all-cause mortality in acute myocardial infarction: the BAMI trial. Eur Heart J. 2020;41(38):3702-3710. https://doi.org/10.1093/eurheartj/ehaa651
[17] ^ Bartunek J, Terzic A, Davison BA, et al. Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. Eur Heart J. 2017;38(9):648-660. https://doi.org/10.1093/eurheartj/ehw543
[18] ^ Norgren L, Weiss N, Nikol S, et al. PACE: randomized, controlled, multicentre, multinational, phase III study of PLX-PAD for critical limb ischaemia in patients unsuitable for revascularization: randomized clinical trial. Br J Surg. 2024;111(2). https://doi.org/10.1093/bjs/znad437
[19] ^ Henry TD, Annex BH, McKendall GR, et al. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation. 2003;107(10):1359-65. https://doi.org/10.1161/01.cir.0000061911.47710.8a
[20] ^ Teraa M, Sprengers RW, Schutgens RE, et al. Effect of repetitive intra-arterial infusion of bone marrow mononuclear cells in patients with no-option limb ischemia: the randomized, double-blind, placebo-controlled Rejuvenating Endothelial Progenitor Cells via Transcutaneous Intra-arterial Supplementation (JUVENTAS) trial. Circulation. 2015;131(10):851-60. https://doi.org/10.1161/CIRCULATIONAHA.114.012913
[21] ^ Peeters Weem SM, Teraa M, de Borst GJ, et al. Bone Marrow derived Cell Therapy in Critical Limb Ischemia: A Meta-analysis of Randomized Placebo Controlled Trials. Eur J Vasc Endovasc Surg. 2015;50(6):775-83. https://doi.org/10.1016/j.ejvs.2015.08.018
[22] ^ Fisher SA, Doree C, Mathur A, et al. Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. Cochrane Database Syst Rev. 2016;12(12):CD007888. https://doi.org/10.1002/14651858.CD007888.pub3
[23] ^ The Lancet Editors. Retraction-Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet. 2019;393(10176):1084. https://doi.org/10.1016/S0140-6736(19)30542-2
[24] ^ US Food and Drug Administration. Approved Cellular and Gene Therapy Products. Content current as of 30 October 2026. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products
[25] ^ Shigematsu H, Yasuda K, Iwai T, et al. Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Ther. 2010;17(9):1152-61. https://doi.org/10.1038/gt.2010.51
[26] ^ Pharmaceuticals and Medical Devices Agency (PMDA). List of approved products: regenerative medical products. https://www.pmda.go.jp/english/review-services/reviews/approved-information/0004.html
[27] ^ Japan Agency for Medical Research and Development (AMED). Approval of RiHEART, iPS cell-derived cardiomyocyte transplantation therapy for ischemic cardiomyopathy. Last updated 23 March 2026. https://www.amed.go.jp/en/news/topics/20260220.html
[28] ^ Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182-6. https://doi.org/10.1056/NEJM197111182852108
[29] ^ De Falco S. Antiangiogenesis therapy: an update after the first decade. Korean J Intern Med. 2014;29(1):1-11. https://doi.org/10.3904/kjim.2014.29.1.1
[30] ^ Chang YS, di Tomaso E, McDonald DM, et al. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci U S A. 2000;97(26):14608-13. https://doi.org/10.1073/pnas.97.26.14608
[31] ^ Genentech. AVASTIN (bevacizumab) injection, prescribing information. DailyMed, US National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=939b5d1f-9fb2-4499-80ef-0607aa6b114e
[32] ^ Eli Lilly and Company. CYRAMZA (ramucirumab) injection, prescribing information. DailyMed, US National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c6080942-dee6-423e-b688-1272c2ae90d4
[33] ^ sanofi-aventis U.S. ZALTRAP (ziv-aflibercept) injection, prescribing information. DailyMed, US National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f6725df6-50ee-4b0a-b900-d02ba634395d
[34] ^ Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8(8):592-603. https://doi.org/10.1038/nrc2442
[35] ^ Genentech. LUCENTIS (ranibizumab) injection, prescribing information. DailyMed, US National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de4e66cc-ca05-4dc9-8262-e00e9b41c36d
[36] ^ Regeneron Pharmaceuticals. EYLEA (aflibercept) injection, prescribing information. DailyMed, US National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f96cfd69-da34-41ee-90a9-610a4655cd1c
[37] ^ Carmeliet P, Tessier-Lavigne M. Common mechanisms of nerve and blood vessel wiring. Nature. 2005;436(7048):193-200. https://doi.org/10.1038/nature03875
[38] ^ Ohab JJ, Fleming S, Blesch A, et al. A neurovascular niche for neurogenesis after stroke. J Neurosci. 2006;26(50):13007-16. https://doi.org/10.1523/JNEUROSCI.4323-06.2006
[39] ^ Asante A, Taylor RN. Endometriosis: the role of neuroangiogenesis. Annu Rev Physiol. 2011;73:163-82. https://doi.org/10.1146/annurev-physiol-012110-142158